Masimo Corporation specializes in non-invasive monitoring technologies, primarily focusing on innovative medical devices that measure blood oxygen levels and other vital signs. Its core products include pulse oximeters, non-invasive hemoglobin monitors, and advanced monitoring solutions for hospitals and home care. Major business segments encompass hospital and home healthcare markets, with revenue primarily derived from product sales and recurring service contracts.
The investment profile of Masimo is more aligned with balanced investors, given its focus on stable revenue generation through established products while navigating recent fluctuations in earnings. The absence of dividends and moderate growth potential suggests a cautious approach. Investors may consider a medium to long-term horizon for potential value realization, with liquidity reflecting a moderate level of trading activity.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-05-26 02:50 | Sell | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-18 04:09 | Hold | Sell | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-08 15:26 | — | Hold | Weak fundamentals and mixed momentum signal caution. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-02-17 14:44 | Stifel Nicolaus | Rating Downgraded | — → 180 | 174.8004 |
| 2026-02-17 14:06 | Piper Sandler | Rating Downgraded | — → 180 | 174.78 |
| 2025-12-05 11:11 | Wells Fargo | Target Raised | 187 → 190 | 142.26 |
